3 research outputs found
Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry
Synthetic and natural
cyclic peptides provide a testing ground
for studying membrane permeability in nontraditional drug scaffolds.
Cyclic peptomers, which incorporate peptide and <i>N</i>-alkylglycine (peptoid) residues, combine the stereochemical and
geometric complexity of peptides with the functional group diversity
accessible to peptoids. We synthesized cyclic peptomer libraries by
split-pool techniques, separately permuting side chain and backbone
geometry, and analyzed their membrane permeabilities using the parallel
artificial membrane permeability assay. Nearly half of the side chain
permutations had permeability coefficients (<i>P</i><sub>app</sub>) > 1 × 10<sup>–6</sup> cm/s. Some backbone
geometries enhanced permeability due to their ability to form more
stable intramolecular hydrogen bond networks compared with other scaffolds.
These observations suggest that hexameric cyclic peptomers can have
good passive permeability even in the context of extensive side chain
and backbone variation, and that high permeability can generally be
achieved within a relatively wide lipophilicity range
Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules
Macrocyclic peptides are considered
large enough to inhibit “undruggable” targets, but the
design of passively cell-permeable molecules in this space remains
a challenge due to the poorly understood role of molecular size on
passive membrane permeability. Using split-pool combinatorial synthesis,
we constructed a library of cyclic, per-N-methlyated peptides spanning
a wide range of calculated lipohilicities (0 < <i>A</i>log<i>P</i> < 8) and molecular weights (∼800
Da < MW < ∼1200 Da). Analysis by the parallel artificial
membrane permeability assay revealed a steep drop-off in apparent
passive permeability with increasing size in stark disagreement with
current permeation models. This observation, corroborated by a set
of natural products, helps define criteria for achieving permeability
in larger molecular size regimes and suggests an operational cutoff,
beyond which passive permeability is constrained by a sharply increasing
penalty on membrane permeation
Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules
Macrocyclic peptides are considered
large enough to inhibit “undruggable” targets, but the
design of passively cell-permeable molecules in this space remains
a challenge due to the poorly understood role of molecular size on
passive membrane permeability. Using split-pool combinatorial synthesis,
we constructed a library of cyclic, per-N-methlyated peptides spanning
a wide range of calculated lipohilicities (0 < <i>A</i>log<i>P</i> < 8) and molecular weights (∼800
Da < MW < ∼1200 Da). Analysis by the parallel artificial
membrane permeability assay revealed a steep drop-off in apparent
passive permeability with increasing size in stark disagreement with
current permeation models. This observation, corroborated by a set
of natural products, helps define criteria for achieving permeability
in larger molecular size regimes and suggests an operational cutoff,
beyond which passive permeability is constrained by a sharply increasing
penalty on membrane permeation